Skip to main content
Erschienen in:

20.01.2022 | COVID-19 | Review Zur Zeit gratis

Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection

verfasst von: Arbind Kumar, Aashish Sharma, Narendra Vijay Tirpude, Suresh Sharma, Yogendra S. Padwad, Sanjay Kumar

Erschienen in: Inflammopharmacology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

The year 2020 is characterised by the COVID-19 pandemic that has quelled more than half a million lives in recent months. We are still coping with the negative repercussions of COVID-19 pandemic in 2021, in which the 2nd wave in India resulted in a high fatality rate. Regardless of emergency vaccine approvals and subsequent meteoric global vaccination drives in some countries, hospitalisations for COVID-19 will continue to occur due to the propensity of mutation in SARS-CoV-2 virus. The immune response plays a vital role in the control and resolution of infectious diseases. However, an impaired immune response is responsible for the severity of the respiratory distress in many diseases. The severe COVID-19 infection persuaded cytokine storm that has been linked with acute respiratory distress syndrome (ARDS), culminates into vital organ failures and eventual death. Thus, safe and effective therapeutics to treat hospitalised patients remains a significant unmet clinical need. In that state, any clue of possible treatments, which save patients life, can be treasured for this time point. Many cohorts and clinical trial studies demonstrated that timely administration of immunomodulatory drugs on severe COVID-19 patients may mitigate the disease severity, hospital stay and mortality. This article addresses the severity and risk factors of hypercytokinemia in COVID-19 patients, with special emphasis on prospective immunomodulatory therapies.
Literatur
Zurück zum Zitat Ajayi S, Becker H, Reinhardt H, et al (2018) Ruxolitinib. Small Mol. Hematol. 119–132. Ajayi S, Becker H, Reinhardt H, et al (2018) Ruxolitinib. Small Mol. Hematol. 119–132.
Zurück zum Zitat Bhatraju PK, Ghassemieh BJ, Nichols M et al (2020) COVID-19 in critically ill patients in the Seattle region - case series. N Engl J Med 382:2012–2022CrossRefPubMed Bhatraju PK, Ghassemieh BJ, Nichols M et al (2020) COVID-19 in critically ill patients in the Seattle region - case series. N Engl J Med 382:2012–2022CrossRefPubMed
Zurück zum Zitat Carpio-Orantes LD, Méndez SG, López-Guzmán C et al (2021) (2021) Baricitinib in patients with severe pneumonia due to COVID-19 in Veracruz, Mexico. J Anesth Crit Care Open Access 13(1):17–20CrossRef Carpio-Orantes LD, Méndez SG, López-Guzmán C et al (2021) (2021) Baricitinib in patients with severe pneumonia due to COVID-19 in Veracruz, Mexico. J Anesth Crit Care Open Access 13(1):17–20CrossRef
Zurück zum Zitat Clyne B, Olshaker JS (1999) The C-reactive protein. J Emerg Med 17(6):1019–25. pmid:10595891 Clyne B, Olshaker JS (1999) The C-reactive protein. J Emerg Med 17(6):1019–25. pmid:10595891
Zurück zum Zitat D’Alessio A, Del Poggio P, Bracchi F et al (2021) Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. Leukemia 35:635–638CrossRefPubMed D’Alessio A, Del Poggio P, Bracchi F et al (2021) Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. Leukemia 35:635–638CrossRefPubMed
Zurück zum Zitat Della-Torre E, Campochiaro C, Cavalli G SARI-RAF Study Group, et al (2020) Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the Rheumatic Diseases, 79:1277–1285. Della-Torre E, Campochiaro C, Cavalli G SARI-RAF Study Group, et al (2020) Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the Rheumatic Diseases, 79:1277–1285.
Zurück zum Zitat Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, R-C Investigators et al (2021) Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 384(16):1491–1502CrossRefPubMed Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, R-C Investigators et al (2021) Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 384(16):1491–1502CrossRefPubMed
Zurück zum Zitat Kewana T, Covuta F, AlJaghbeerb MJ et al (2020) Tocilizumab for treatment of patients with severe COVID19: A retrospective cohort study. Clinical Medicine 24:100418 Kewana T, Covuta F, AlJaghbeerb MJ et al (2020) Tocilizumab for treatment of patients with severe COVID19: A retrospective cohort study. Clinical Medicine 24:100418
Zurück zum Zitat Ko J-H, Park GE, Lee JY, et al (2016) Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients. J Infect 73(5):468–75. pmid:27519621 Ko J-H, Park GE, Lee JY, et al (2016) Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients. J Infect 73(5):468–75. pmid:27519621
Zurück zum Zitat Liu T., Zhang J., Yang Y., Ma H., et al., (2020) The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv. 2020;2020 03.01.20029769 Liu T., Zhang J., Yang Y., Ma H., et al., (2020) The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv. 2020;2020 03.01.20029769
Zurück zum Zitat Marconi VC, Ramanan AV, de Bono S et al (2021) Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 9(10): Marconi VC, Ramanan AV, de Bono S et al (2021) Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 9(10):
Zurück zum Zitat Matthay MA et al (2019) Acute respiratory distress syndrome. Nat Rev Dis Primers 371(5):372 Matthay MA et al (2019) Acute respiratory distress syndrome. Nat Rev Dis Primers 371(5):372
Zurück zum Zitat Mortara A, Mazzetti S, Margonato D et al., (2021) Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation Clin Transl Sci. 2021;14:1062–1068 Mortara A, Mazzetti S, Margonato D et al., (2021) Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation Clin Transl Sci. 2021;14:1062–1068
Zurück zum Zitat Vannucchi AM, Mortara A, D'Alessio A, et al. (2021 b) JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. J Clin Med. 2021;10(16):3752. https://doi:https://doi.org/10.3390/jcm10163752 Vannucchi AM, Mortara A, D'Alessio A, et al. (2021 b) JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. J Clin Med. 2021;10(16):3752. https://​doi:https://​doi.​org/​10.​3390/​jcm10163752
Zurück zum Zitat Wang J-T, Sheng W-H, Fang C-T et al (2004) Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 10(5):818–24CrossRefPubMedPubMedCentral Wang J-T, Sheng W-H, Fang C-T et al (2004) Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 10(5):818–24CrossRefPubMedPubMedCentral
Metadaten
Titel
Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection
verfasst von
Arbind Kumar
Aashish Sharma
Narendra Vijay Tirpude
Suresh Sharma
Yogendra S. Padwad
Sanjay Kumar
Publikationsdatum
20.01.2022
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Inflammopharmacology / Ausgabe 1/2022
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-021-00903-x